Drug Trial Radar · NCT06746519
BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Dec 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
Dec 25, 2024
Primary completion
Dec 30, 2025
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Chen SuningAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- BioNova Pharmaceuticals (Shanghai) LTD.
- First posted
- Dec 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken twice daily combined with Intensive Chemotherapy or Venetoclax/Azacitidine in patients with acute myeloblastic leukemia.
Conditions
- Acute Myeloid Leukemia
Interventions
BN104 combined Intensive Chemotherapy or Venetoclax/AzacitidineDrug
The starting dose cohort(200mg BID N104) combined Intensive Chemotherapyor Venetoclax/Azacitidine. Each treatment cycle is anticipated to be 28 days in length, although cycle delays may be made due to delayed count recovery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability of BN104 in combination with Venetoclax/Azacitidine or intensive chemotherapyTime frame: At the end of Cycle1 (Cycle1 Day28)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.